Cita APA (7a ed.)
Chen, C., Tsai, J., Tsai, S., Chen, L., & Yang, S. (2026). Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAF V600E -Mutated Metastatic Lung Cancer. Current Oncology, 33(7), 384-395.
Cita Chicago Style (17a ed.)
Chen, Chian-Wei, Jui-Hung Tsai, Sheng-Han Tsai, Li-Jun Chen, y Szu-Chun Yang. "Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAF V600E -Mutated Metastatic Lung Cancer." Current Oncology 33, no. 7 (2026): 384-395.
Cita MLA (9a ed.)
Chen, Chian-Wei, et al. "Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAF V600E -Mutated Metastatic Lung Cancer." Current Oncology, vol. 33, no. 7, 2026, pp. 384-395.
Precaución: Estas citas no son 100% exactas.